Phaseline

Targets › JAK1

JAK1 (Tyrosine-protein kinase JAK1): drug programs, companies and trials

30 programs from 25 companies in 271 trials: 118 Phase 2, 69 Phase 3, 61 Phase 1, 23 Phase 4; Immunology, Oncology, Other; next expected readout Nov 2026.

Non-membrane spanning protein tyrosine kinase that phosphorylates signal-transducing subunits of cytokine receptor complexes like IL2RB, IL10RA, IFNAR2, IL6ST, LIFR, OSMR and IL31RA. Functionally, is involved in the IFN-alpha/beta/gamma signal pathway. Mechanistically, in response to interferon-binding to IFNAR1-IFNAR2 heterodimer, phosphorylates and activates its binding partner IFNAR2, creating docking sites for…. (UniProt, P23458)

Open in Phaseline: the race on JAK1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TakedaTofacitinib
Janus Kinase (JAK) inhibitor
JAK3, JAK1, JAK2, TYK2Phase 4Ulcerative Colitis; Rheumatoid Arthritis; Axial Spondyloarthritis; Oral Lichen Planus …Jul 2027
EisaiFilgotinib Maleate
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor
JAK1, JAK2, TYK2, JAK3Phase 4Ulcerative ColitisNov 2027
IncyteRuxolitinib
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor
JAK1, JAK2, JAK3, TYK2Phase 3NonSegmental Vitiligo; Hidradenitis Suppurativa; Atopic Dermatitis; Graft-versus-host Disease (GVHD) …Nov 2026
AbbVieUpadacitinib
Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor
TYK2, JAK3, JAK2, JAK1Phase 3Atopic Dermatitis; Systemic Lupus Erythematosus; Ulcerative Colitis (UC); Crohn's Disease …Nov 2026
Incytepovorcitinib
JAK1 inhibitor
JAK1Phase 3Hidradenitis Suppurativa (HS); NonSegmental Vitiligo; Prurigo Nodularis; Moderate to Severe Asthma …Nov 2026
Jiangsu HengRui MedicineSHR0302
JAK1 inhibitor
JAK1Phase 3Psoriatic Arthritis; Non-segmental VitiligoDec 2026
LEO PharmaDelgocitinib
Janus Kinase (JAK) inhibitor
JAK3, JAK1, JAK2, TYK2Phase 3Lichen Sclerosus; Palmoplantar Pustulosis; Central Centrifugal Cicatricial Alopecia; VitiligoDec 2026
Chia Tai Tianqing Pharmaceutical GroupTQ05105 Tablets (Rovadicitinib Tablets)
Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), and Rho-associated coiled-coil containing pr
JAK1, JAK2, ROCK2Phase 3Graft-versus-host Disease; Chronic Graft Versus Host Disease; MyelofibrosisDec 2026
Pfizertofacitinib
Janus Kinase (JAK) inhibitor
JAK3, JAK1, JAK2, TYK2Phase 3Ulcerative ColitisMar 2027
PfizerAbrocitinib
Tyrosine-protein kinase JAK1 inhibitor
JAK1Phase 3Eczema; Atopic Dermatitis; Post-COVID Condition; Diabetes Mellitus, Type 1May 2027
Chengdu Zenitar Biomedical TechnologyFlonoltinib Maleate
JAK1/JAK2 inhibitor
JAK1, JAK2Phase 3MF; MF,PMF,PPV-MF,PET-MF; Polycythemia Vera (PV)May 2027
Sun Pharmaceutical IndustriesDeuruxolitinib Phosphate (CTP-543)
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor
JAK1, JAK2, JAK3, TYK2Phase 3Alopecia AreataMay 2027
AlfasigmaFilgotinib
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor
JAK1, JAK2, TYK2, JAK3Phase 3Polyarticular Course Juvenile Idiopathic Arthritis; Juvenile Idiopathic Arthritis (JIA); Ulcerative Colitis; Axial Spondyloarthritis …Jun 2027
Dizal PharmaceuticalsGolidocitinib
Tyrosine-protein kinase JAK1 inhibitor
JAK1Phase 3Peripheral T-cell Lymphoma; T-cell Lymphomas; Peripheral T Cell Lymphoma; Maintenance Treatment of Peripheral T-cell Lymphoma …Nov 2027
Priovant TherapeuticsBrepocitinib
JAK1 inhibitor
JAK1Phase 3Uveitis, Posterior; Lichen Planopilaris; Cutaneous SarcoidosisFeb 2028
Sun Pharma JapanDeuruxolitinib
JAK1 inhibitor
JAK1Phase 3Alopecia AreataFeb 2028
Eli LillyBaricitinib (LY3009104)
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor
JAK1, JAK2Phase 3Systemic Juvenile Idiopathic Arthritis; Areata Alopecia; Diabetes Mellitus, Type 1; Uveitis …Mar 2028
Suzhou Zelgen BiopharmaceuticalsJaktinib Hydrochloride Tablet
JAK inhibitor
JAK1, JAK2, JAK3Phase 3Atopic Dermatitis–
IncyteItacitinib
Tyrosine-protein kinase JAK1 inhibitor
JAK1Phase 2B-Cell Malignancies; Systemic Sclerosis; Diffuse Large B Cell Lymphoma; Acute Lymphoblastic Leukemia …Nov 2026
Institute of Hematology & Blood Diseases Hospital, ChinaGolidocitnib
JAK1 inhibitor
JAK1Phase 2Lymphoma, T-CellNov 2026
GSKMomelotinib
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Activin receptor type-1 inhibitor
JAK1, JAK2, ACVR1Phase 2Primary Myelofibrosis; Myelodysplastic Syndromes; VEXAS Syndome; Myeloid Leukemia …Dec 2026
M.D. Anderson Cancer CenterRuxolitinib Phosphate
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor
JAK1, JAK2, JAK3, TYK2Phase 2Splenomegaly; AML; Chronic Lymphocytic Leukemia; T-cell Prolymphocytic Leukemia …Jan 2027
Fudan UniversitySHR-0302
JAK inhibitor
JAK1, JAK2, JAK3Phase 2Relapsed/Refractory Peripheral T Cell LymphomaFeb 2027
City of Hope Medical CenterRuxolitinib Phosphate
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor
JAK1, JAK2, JAK3, TYK2Phase 2Acute Lymphoblastic Leukemia; Follicular Helper T-Cell Lymphoma; Hematopoietic and Lymphatic System NeoplasmMar 2027
Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineIvarmacitinib
Selective JAK1 inhibitor
JAK1Phase 2Graft-Versus-Host Disease(GVHD)May 2028
Second Affiliated Hospital, Zhejiang University, School of MedicineEmactinib Sulfate
JAK1 inhibitor
JAK1Phase 2Head and Neck Cancer Squamous Cell CarcinomaAug 2028
Second Affiliated Hospital, Zhejiang University, School of MedicineIvarmacitinib
JAK inhibitor
JAK1, JAK2Phase 2Esophageal Squamous Cell CarcinomaDec 2028
Shixiu WuJAK Inhibitors
Janus kinase inhibitors
JAK1, JAK2, JAK3, TYK2Phase 2Immune Checkpoint Inhibitors (ICI)-Related Dermatitis–
AbbVieTofacitinib
Janus Kinase (JAK) inhibitor
JAK3, JAK1, JAK2, TYK2Phase 1Healthy VolunteersDec 2026
First Affiliated Hospital of Zhejiang UniversityGecacitinib (also known as Jaktinib)
JAK inhibitor
JAK1, JAK2, JAK3Phase 1Acute Graft Versus Host DiseaseDec 2027

Conditions

Atopic Dermatitis (9) Rheumatoid Arthritis (9) Myelofibrosis (8) Acute Lymphoblastic Leukemia (7) Ulcerative Colitis (6) Alopecia Areata (5) Rheumatoid Arthritis (RA (4) Vitiligo (4) NonSegmental Vitiligo (4) Hidradenitis Suppurativa (4) Primary Myelofibrosis (4) Chronic Graft Versus Host Disease (3)

Modalities

small molecule (26), mixed (2), antibody (1)

Companies

Incyte (3) Pfizer (2) Second Affiliated Hospital, Zhejiang University, School of Medicine (2) AbbVie (2) First Affiliated Hospital of Zhejiang University (1) Chia Tai Tianqing Pharmaceutical Group (1) Sun Pharmaceutical Industries (1) Dizal Pharmaceuticals (1) Alfasigma (1) Takeda (1) Chengdu Zenitar Biomedical Technology (1) Eli Lilly (1) LEO Pharma (1) Priovant Therapeutics (1) Institute of Hematology & Blood Diseases Hospital, China (1) GSK (1) Eisai (1) Jiangsu HengRui Medicine (1) City of Hope Medical Center (1) Shixiu Wu (1)

Related targets

JAK2 (20) JAK3 (15) TYK2 (12) ROCK2 (1) ACVR1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.